AcelRx Pharmaceuticals

AcelRx Pharmaceuticals R&D per Employee

Delisted

The R&D Spending per Employee of AcelRx Pharmaceuticals (ACRX) as of Nov 3, 2026 is 462,166.67 USD. In the previous year, R&D Spending per Employee was 432,750.00 USD — a change of 6.80% (higher).

R&D per Employee

462,166.67USD

YoY

6.80%

Last updated:

R&D Spending per Employee of AcelRx Pharmaceuticals is 2023 462,166.67 USD. R&D Spending per Employee of AcelRx Pharmaceuticals was 2022 432,750.00 USD. It decreases by 6.80% higher compared to the previous year.

The AcelRx Pharmaceuticals R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2016
1.78 M USD
Jan 1, 2017
1.62 M USD
Jan 1, 2018
1.09 M USD
Jan 1, 2019
388,416.67 USD
Jan 1, 2020
334,750.00 USD
Jan 1, 2021
341,250.00 USD
Jan 1, 2022
432,750.00 USD
Jan 1, 2023
462,166.67 USD
The AcelRx Pharmaceuticals R&D per Employee history
YEARR&D per EmployeeYoY
462,166.67USD+6.80%
432,750.00USD+26.81%
341,250.00USD+1.94%
334,750.00USD-13.82%
388,416.67USD-64.52%
1.09 MUSD-32.31%
1.62 MUSD-9.31%
1.78 MUSD-4.83%
1.87 MUSD-8.29%
2.04 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

AcelRx Pharmaceuticals Stock analysis

What does AcelRx Pharmaceuticals do? AcelRx Pharmaceuticals Inc. is a California-based company specializing in the manufacturing of pain relief medications. The company was founded in 2005 and has since become an innovator in the development of pain medications. AcelRx's business model involves selling its patented products to hospitals and other healthcare facilities, and it is currently expanding into the global market. The company focuses on developing pain medications for emergency medicine and palliative care, with a particular emphasis on delivering medications through sprays or injections for fast-acting relief. AcelRx offers products such as Zalviso, a pain reliever based on Fentanyl nasal sprays used for post-operative pain, and Dsuvia, a sublingual tablet containing the active ingredient Sufentanil for severe pain. The FDA has approved Dsuvia as safe and effective. AcelRx has also entered partnerships with other pharmaceutical companies, such as Grünenthal and Chinese company R-Pharm, to bring its products to the international market. The company is committed to investing in research and development for innovative pain relief solutions, including a new research program targeting the development of medications for neuropathic pain. AcelRx Pharmaceuticals is a positive example of how modern pharmaceuticals can improve healthcare and quality of life. The company has demonstrated its potential through dedication and continuous research and development, and it is likely to make even greater contributions in the future. AcelRx Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AcelRx Pharmaceuticals stock

R&D Spending per Employee of AcelRx Pharmaceuticals is 462,166.67 USD in 2023.

R&D Spending per Employee of AcelRx Pharmaceuticals changed from 432,750.00 USD to 462,166.67 USD, representing a 6.80% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee AcelRx Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's AcelRx Pharmaceuticals historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — AcelRx Pharmaceuticals

All Key Metrics — AcelRx Pharmaceuticals